Article info
PDFOriginal research
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report
- Correspondence to Professor Fátima Falcão, Pharmacy, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa 1449-005, Portugal; mffalcao{at}chlo.min-saude.pt
Citation
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report
Publication history
- Received November 23, 2020
- Revised December 16, 2020
- Accepted January 4, 2021
- First published January 15, 2021.
Online issue publication
August 23, 2021
Article Versions
- Previous version (15 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage